ArticleCurrent microbiology2023
The Influence of Probiotics in Reducing Cisplatin-Induced Toxicity in Zebrafish (Danio rerio).
Article in Current microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, the effects of probiotic supplementation on cisplatin toxicity in zebrafish (Danio rerio) were examined. For this study, adult female zebrafish were given cisplatin (G2), the probiotic, Bacillus megaterium (G3), and cisplatin+B. megaterium (G4) for 30 days, in addition to the control (G1). In order to investigate changes in antioxidative enzymes, ROS production, and histological changes after treatment, the intestines and ovaries were excised. The levels of lipid peroxidation, glutathione peroxidase, glutathione reductase, catalase, and superoxide dismutase were found to be significantly higher in the cisplatin group than in the control group in both the intestine and the ovaries. Administration of the probiotic and cisplatin effectively reversed this damage. Histopathological analyses showed that the cisplatin group had much more damage than the control group and that probiotic+cisplatin treatment significantly cured these damages. It opens the door to probiotics being combined with cancer-related drugs, which may be a more efficient approach for minimizing side effects. The underlying molecular mechanisms of probiotics must be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.